Dedicated to Helping People Survive Cancer
Powered by a passion to effect dramatic improvements in cancer survival rates, NanoCytomics’ team members are developing novel, highly accurate, low-cost, non-invasive tests for use in primary care physicians’ offices.
The company intends to revolutionize the risk stratification of patients, helping physicians identify those likely to benefit from gold-standard diagnostic procedures as early as possible, when cancer treatments can be the most effective. NanoCytomics anticipates offering its first commercially available Laboratory Developed Test (LDT) for cancer risk stratification in 2018.
Learn more about NanoCytomics’ technology platform. Stay in touch with the site’s Contact Us and Alerts functions.